US WorldMeds
Private US company that took over Tecelra and lete-cel from Adaptimmune in 2025 and markets eflornithine (Iwilfin) for neuroblastoma.
Acquired Adaptimmune's cell-therapy assets (afamitresgene autoleucel; letetresgene autoleucel, BLA committed by end-2026) in August 2025; markets Iwilfin (eflornithine, approved December 2023 for high-risk neuroblastoma maintenance).
Afamitresgene autoleucel was the first engineered T-cell receptor therapy approved for a solid tumour, synovial sarcoma.
Letetresgene autoleucel is a second engineered T-cell receptor therapy for sarcoma, targeting NY-ESO-1 in synovial sarcoma and myxoid/round cell liposarcoma; a BLA is expected by the end of 2026.
Eflornithine (DFMO) is an old sleeping-sickness drug repurposed as the first oral maintenance therapy for high-risk neuroblastoma, approved in December 2023 to reduce relapse after immunotherapy.
Pages like this
not linked directly; found by shared links- TrialNMTRC003/003B (DFMO maintenance)
Shares Eflornithine (DFMO), No incentive to repurpose cheap drugs, Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- IdeaExtending sarcoma TCR-T beyond HLA-A*02
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- Key paperSPEARHEAD-1: afami-cel, the first engineered T-cell receptor therapy approved for a solid tumour, in synovial sarcoma
Shares Letetresgene autoleucel, Afamitresgene autoleucel, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TermMYCN amplification
Shares Eflornithine (DFMO), Neuroblastoma (paediatric), Rare and paediatric cancers without markets.
- TrialIGNYTE-ESO
Shares Letetresgene autoleucel, Sarcomas (soft tissue, bone, GIST).
- IdeaPay a prize for rare cancer drugs instead of hoping for a market
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOpen-source drug discovery to clinical proof of concept for neglected cancers
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaAn international consortium pooling the outcome of every treated child with cancer
Shares Neuroblastoma (paediatric), Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).